SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
168.11
+0.32 (+0.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close167.79
Open168.79
Bid167.00 x 800
Ask168.50 x 800
Day's range166.82 - 170.84
52-week range59.57 - 195.97
Volume386,339
Avg. volume551,557
Market cap7.82B
Beta3.74
PE ratio (TTM)N/A
EPS (TTM)-7.22
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est208.64
Trade prices are not sourced from all markets
  • Sage Therapeutics’ GABA Receptor–Based Products
    Market Realist2 days ago

    Sage Therapeutics’ GABA Receptor–Based Products

    As we discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders, based on two different programs: GABA receptor systems and NMDA receptor systems. The chart below shows the product portfolio for the GABA Receptor program. 

  • Sage Therapeutics’ Product Portfolio in July
    Market Realist3 days ago

    Sage Therapeutics’ Product Portfolio in July

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors. 

  • Sage Therapeutics: Analysts’ Estimates and Recommendations
    Market Realist3 days ago

    Sage Therapeutics: Analysts’ Estimates and Recommendations

    Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company. Sage Therapeutics develops medicines for the treatment of life-altering central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • Cramer Remix: Investors can't see the reality of this market
    CNBC3 days ago

    Cramer Remix: Investors can't see the reality of this market

    Jim Cramer makes the case to value the market just as it is.

  • 3 Top Biotech Stocks to Buy for the 2nd Half of 2018
    Motley Fool8 days ago

    3 Top Biotech Stocks to Buy for the 2nd Half of 2018

    Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.

  • Business Wire10 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • SAGE Therapeutics’ NMDA Receptor–Based Portfolio
    Market Realist28 days ago

    SAGE Therapeutics’ NMDA Receptor–Based Portfolio

    As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.

  • SAGE Therapeutics’ GABA Receptor–Based Portfolio
    Market Realist28 days ago

    SAGE Therapeutics’ GABA Receptor–Based Portfolio

    As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.

  • A Look at SAGE Therapeutics’ Product Portfolio
    Market Realistlast month

    A Look at SAGE Therapeutics’ Product Portfolio

    SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.

  • SAGE Therapeutics’ Strategic Collaboration with Shionogi
    Market Realistlast month

    SAGE Therapeutics’ Strategic Collaboration with Shionogi

    On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.

  • SAGE Therapeutics’ Stock Performance and Estimates in June
    Market Realistlast month

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • MarketWatchlast month

    Sage shares drop 3% after $90 mln Shionogi deal for key drug

    Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.

  • Business Wirelast month

    Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.

  • Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug
    Investor's Business Dailylast month

    Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug

    Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.

  • Company News For Jun 13, 2018
    Zackslast month

    Company News For Jun 13, 2018

    Companies In The News are: TSLA,SAGE,RH,PLAY

  • Here's Why Sage Therapeutics Rose as Much as 20.3% Today
    Motley Foollast month

    Here's Why Sage Therapeutics Rose as Much as 20.3% Today

    The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.

  • Is Sage Therapeutics Inc’s (NASDAQ:SAGE) Liquidity Good Enough?
    Simply Wall St.last month

    Is Sage Therapeutics Inc’s (NASDAQ:SAGE) Liquidity Good Enough?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Sage Therapeutics Inc (NASDAQ:SAGE), with a market capitalization of US$6.92B, rarely draw their attention from the investingRead More...

  • Why Tesla, Sage Therapeutics, and Lands' End Jumped Today
    Motley Foollast month

    Why Tesla, Sage Therapeutics, and Lands' End Jumped Today

    Find out which of these stocks made the biggest move higher.

  • Why This Biotech Company Is Bounding Closer To A Breakout
    Investor's Business Dailylast month

    Why This Biotech Company Is Bounding Closer To A Breakout

    Sage Therapeutics bounded closer to a break out Tuesday after the biotech company outlined its expedited path to approval for a depression treatment.

  • Sage shares surge 15% after FDA OKs expedited depression drug development
    CNBClast month

    Sage shares surge 15% after FDA OKs expedited depression drug development

    Sage Therapeutics says the FDA has cleared it to expedite development of its drug to treat major depressive disorder and postpartum depression.

  • MarketWatchlast month

    Sage shares surge 4.5% on plan to expedite drug development for two types of depression

    Sage Therapeutics Inc. shares surged 4.5% in premarket trade Tuesday on news that the company met with the Food and Drug Administration and now plans to expedite development of its SAGE-217 drug in two areas of depression, major depressive disorder and postpartum depression. Sage plans one new phase 3 trial in major depressive disorder, which will likely begin in the second half of this year, to support a FDA filing for the indication. It also plans to use an ongoing trial for postpartum depression, for which early results are expected in the fourth quarter, to support another filing.

  • GlobeNewswirelast month

    Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics, Harris, and A-Mark Precious Metals — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cheniere ...

  • Business Wirelast month

    Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA). This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). The expedited development plan for SAGE-217 includes a single additional placebo-controlled Phase 3 pivotal trial in patients with MDD and the ongoing placebo-controlled trial in women with PPD, now designated a pivotal trial.

  • Business Wirelast month

    Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M.

  • Business Wirelast month

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 59,600 shares of its common stock to eleven new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.